ReviewDrugs2011
Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.
Review in Drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 70 citations in OpenAlex.
- Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer.Journal of cancer research and clinical oncology · 2021Trial
- N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Trial
- Article
- What Is Known about Breast Cancer in Young Women?Cancers · 2023Review
- Article
- Detection of Estrogen Receptor Alpha and Assessment of Fulvestrant Activity in MCF-7 Tumor Spheroids Using Microfluidics and SERS.Analytical chemistry · 2021Article
- Applications of Bacterial Degrons and Degraders - Toward Targeted Protein Degradation in Bacteria.Frontiers in molecular biosciences · 2021Review
- Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist's Perspective.Angewandte Chemie (International ed. in English) · 2020Review
- Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy.Drugs · 2018Review
- Novel Strategies to Improve the Endocrine Therapy of Breast Cancer.Oncology reviews · 2017Review
- Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.Cell cycle (Georgetown, Tex.) · 2017Article
- Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI.Scientific reports · 2016Article
- Manganese Superoxide Dismutase Acetylation and Dysregulation, Due to Loss of SIRT3 Activity, Promote a Luminal B-Like Breast Carcinogenic-Permissive Phenotype.Antioxidants & redox signaling · 2016Review
- Systemic treatment in breast cancer: a primer for radiologists.Insights into imaging · 2016Article
- Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.Angewandte Chemie (International ed. in English) · 2015Article
- Three-component synthesis of C2F5-substituted pyrazoles from C2F5CH2NH2·HCl, NaNO2 and electron-deficient alkynes.Beilstein journal of organic chemistry · 2015Article
- Considerations for payers in managing hormone receptor-positive advanced breast cancer.ClinicoEconomics and outcomes research : CEOR · 2014Review
- Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides.Bioorganic & medicinal chemistry letters · 2013Article
- Hormonal therapies in young breast cancer patients: when, what and for how long?Journal of thoracic disease · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fulvestrant (Faslodex®) is an intramuscularly administered steroidal estrogen receptor antagonist that is devoid of any known estrogen agonist effects. It is indicated as second-line therapy for the treatment of postmenopausal women with hormone receptor-positive advanced breast cancer who have progressed following prior endocrine therapy. In well designed, randomized clinical trials, regimens of fulvestrant 250 and 500 mg provided effective second-line therapy for postmenopausal women with advanced breast cancer who had progressed following prior endocrine therapy. Moreover, fulvestrant 250 mg monthly (with or without a loading dose) was as effective as aromatase inhibitor therapy. However, fulvestrant is absorbed slowly, and greater steady-state concentrations are achieved more rapidly when using a higher dosage with a loading dose regimen. Consequently, a regimen of fulvestrant 500 mg monthly with a loading dose was significantly more effective than a regimen of 250 mg monthly in postmenopausal women with disease progression. Limited data also indicate a potential role for the fulvestrant 500 mg regimen as first-line therapy. Fulvestrant is generally well tolerated with no additional adverse events noted with the high-dose regimen compared with the 250 mg regimens. Furthermore, the incidence of joint disorders was shown to be significantly lower with fulvestrant 250 mg monthly than with anastrozole. Treatment with fulvestrant is not associated with any clinically significant effects on endometrial thickening, bone-specific turnover markers or sex hormone levels. In conclusion, a monthly regimen of intramuscular fulvestrant 500 mg with a loading dose provides effective and well tolerated second-line therapy for postmenopausal women with advanced breast cancer who have progressed following prior endocrine therapy and is now the approved optimal dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.